Vazyme

Executive Summary

Vazyme is a leading Chinese biotechnology company specializing in the development and production of diagnostic reagents and instruments, with a focus on enzymes, antibodies, and bio-reagents for clinical diagnostics and life science research. Founded in 2012 and headquartered in Nanjing, the company has grown to over 1,000 employees and operates as a public commercial-stage entity. Vazyme offers a comprehensive portfolio spanning molecular diagnostics, immunodiagnostics, and next-generation sequencing (NGS), serving both the domestic and international markets. Its core competitive advantage lies in its proprietary enzyme engineering and antibody development capabilities, which enable high-performance, cost-effective solutions for diagnostic applications. The company is well-positioned to benefit from China's expanding healthcare market and increasing demand for precision medicine, as well as global trends toward localized supply chains for critical bio-reagents. With a strong R&D pipeline and a track record of commercial success, Vazyme represents a compelling player in the diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for new molecular diagnostics kit80% success
• Q4 2026Launch of next-generation sequencing (NGS) reagent suite70% success
• Q2 2026Strategic partnership with global diagnostics distributor for international expansion60% success